FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $2.25. This compares to a loss of $4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.22%. A quarter ago, it was expected that this biotech drug developer would post earnings of $0.75 per share when it actually produced a loss of $4, delivering a surprise of -633.33%.Over the last four quarters, the company has ...